JCJacie T. Cooper

Jacie T. Cooper

*This is an algorithmically generated author record based on publicly available information.

Jacie T. Cooper has a total of 9 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Cost-effectiveness analysis of a prognostic risk assessment for early-stage 1-3b diabetic kidney disease patients in the United States

    by Jacie T. Cooper, John E. Schneider, Thomas Mclain, Steven Coca, Michael J. Donovan

    Background: Diabetic kidney disease (DKD) accounts for 44% of new chronic kidney disease cases and is associated with significant morbidity and mortality. Although sodium-glucose co-transporter-2 inhibitors (SGLT2is) can reduce cardiorenal outcomes, current DKD staging relying on eGFR and albuminuria (KDIGO risk categories) leaves SGLT2is underutilized in clinical practice. A new biomarker-enriched, AI-enabled risk score (KidneyIntelX™; Renalytix, Inc.) was developed to predict a progressive decline in kidney function in patients with early-stage DKD. KidneyIntelX categorizes patients as low, intermediate, or high risk for disease progression, which can guide resource utilization, prescribing of drugs such as SGLT2is, and improvements in efficiency of care. We report a cost-effectiveness analysis comparing DKD patient stratification with KidneyIntelX to KDIGO by generating an incremental cost effectiveness ratio (ICER). Methods: The model adopted a U.S. Medicare perspective and consisted of patients with DKD in stages G1-3b using KidneyIntelX or KDIGO. A 10-state Markov state transition structure was employed over a lifetime horizon which includes DKD stages 1–5, dialysis, kidney transplant, cardiovascular (CV) death, and non-CV death. Transition probabilities and risk group distributions for KidneyIntelX and KDIGO were sourced from a KidneyIntelX validation study. Evaluation resulting from KidneyIntelX or KDIGO informed SGLT2i use in the model. Cost inputs included testing, medications, and office visit costs, as well as annual costs for each DKD stage, dialysis, and kidney transplant. Quality of life for each disease state was captured as utility values informed by literature. Results: The modeled use of SGLT2i directed by KidneyIntelX led to a reduction in kidney disease progression (ESKD) and CV events, as well as dialysis starts, dialysis crashes, and kidney transplants compared to KDIGO-guided treatment. KidneyIntelX patients also spent less time in DKD stages 4 and 5 and more time in 1 through 3b. KidneyIntelX led to cost savings of about $514 per patient and quality-adjusted life year (QALY) gains of 0.028, resulting in a negative ICER. Combining SGLT2i with MRA’s further increased per patient cost savings to $530 for Medicare participants. Conclusions: Wide deployment of KidneyIntelX in Medicare patients with DKD G1-3b is expected to be cost-effective compared to KDIGO from the Medicare perspective, with a negative, dominant ICER.

  • Open Access

    Cost Impact of a Novel Pre-transplant Risk Assessment Tool for Early Acute Rejection in Kidney Transplant Patients

    by Jacie T. Cooper, John E. Schneider

    Background: Accurately predicting outcomes and stratifying risks remains a challenge in kidney transplant patients. The Pre-Transplant Risk Assessment (PTRA) predicts risk of early acute rejection (EAR) in deceased donor transplant recipients, enabling clinicians to tailor immunosuppression strategies using individual immune response risk. Objectives: We developed a cost-impact analysis of adding PTRA to the current standard of care to predict the risk of EAR compared with the current protocol-driven immunosuppression in standard-risk kidney transplant patients. Methods: A decision tree model evaluated 90-day and 2-year outcomes post kidney transplantation. PTRA testing stratified patients as either high or low risk for EAR. Reduced maintenance immunosuppression protocols were modeled in low-risk PTRA patients compared with standard protocol, reducing adverse drug event readmissions, cytomegalovirus infections, graft loss, and deaths with a functioning graft. An increased maintenance immunosuppressive regimen was modelled for high-risk PTRA patients, reducing acute rejections and graft loss. Results: The standard-risk population cohort consisted of 71.4% low-risk PTRA and 28.6% high-risk PTRA patients. The model generated per-patient cost savings of $358 in the first 90 days post transplantation and $13 234 per-patient over 2 years. If PTRA were used in all 14 468 patients falling into the standard risk immunosuppression protocol, $191 475 915 could be saved over 2 years at the cohort level. If PTRA were to impact induction immunosuppression protocols, per-patient savings would exceed $4000 over 90 days and $27 000 over 2 years. The definitions used for risk stratification and the assumed immunosuppression protocols for patient cohorts are generalized assumptions expected to align with most clinician approaches. We assumed that the reduction on clinical outcomes would be equivalent to the overall percentage of patients with expected treatment regimen impacts from PTRA. Variations in clinical decision-making regarding treatment pathways given PTRA risk stratification will influence the potential clinical impact. Conclusions: Risk stratification with PTRA utilization prior to kidney transplant in the standard-risk population could generate significant cost savings in the 90-day and 2-year time periods post kidney transplantation.

  • Open Access

    Economic Evaluation of a Novel MicroRNA-Based Assay to Determine Risk of Late Genitourinary Radiation Toxicity in Patients With Prostate Cancer

    by Jacie T. Cooper, John E. Schneider

    Background: Prostate cancer is one of the most common malignancies in men, and radiation therapy, most often stereotactic body radiation therapy or conventionally fractionated radiotherapy, is a standard curative treatment for advanced cases. Although genitourinary toxicity is a known side effect, with acute symptoms typically resolving and late toxicity causing lasting harm, individual risk varies substantially. However, no validated tool exists to predict patient-specific toxicity across radiation modalities, leaving treatment decisions to be made without personalized risk insights. Objective: The goal of this analysis was to estimate changes in cost and quality of life associated with reductions in late genitourinary toxicity attributable to personalized radiation therapy in individuals with prostate cancer. Implementation of PROSTOX ultra , a novel microRNA-based assay for toxicity risk assessment with stereotactic body radiation therapy, is expected to enable the personalization of radiation therapy, helping patients avoid toxic effects from specific types of radiation therapy. Methods: This study utilizes a hybrid decision-tree and Markov model approach to estimate the 5-year cost-impact and lifetime cost-effectiveness in prostate cancer patients of PROSTOX ultra vs current treatment standards that do not include toxicity risk assessment. High or low risk assessment influences whether patients receive stereotactic body radiation therapy, conventionally fractionated radiotherapy, or prostatectomy, impacting toxicity-related treatment costs and quality-of-life decrements. Results: Over 5 years, PROSTOX ultra patients totaled $47 683 in costs vs $67 298 with standard-care risk assessment. Cumulative savings over 5 years were $19 615 per tested patient. Over a lifetime, PROSTOX ultra was expected to save about $24 777 per tested patient while adding 0.24 quality-adjusted life-years compared with patients tested using standard assessment. Conclusions: Model results indicate that toxicity risk assessment with PROSTOX ultra would be cost saving over 5 years compared with standard risk assessment. Cost-effectiveness results show cost savings and quality-adjusted life-year gains over a lifetime, indicating that PROSTOX ultra would be a dominant strategy compared with treatment without risk assessment.

  • Open Access

    Economic Evaluation of a Novel Treatment of Attention-Deficit/Hyperactivity Disorder in US Motor Vehicle Drivers

    by Jacie T. Cooper, John E. Schneider, Jim Potenziano, David S. Fam

    Background: Attention-deficit/hyperactivity disorder (ADHD) affects approximately 4.4% of US adults. ADHD is associated with high-risk driving behavior and costly motor vehicle accidents. DYANAVEL XR (DXR) (Tris Pharma, Inc.) is a once-daily fast-acting amphetamine developed for ADHD treatment. A randomized controlled trial showed that DXR patients were 43% less likely to crash during a driving simulation than individuals taking placebo. Study outcomes suggest a DXR crash rate similar to that of a driver without ADHD, while patients treated with the current standard of care (SOC) have a 52% higher crash risk than non-ADHD drivers. Objective: The aim was to evaluate the economic benefits attributable to improved driving abilities and avoided crashes in DXR patients compared with patients treated with the SOC or those who are untreated. Methods: A cost-impact model estimated 1-year crash-related cost outcomes for DXR-treated patients compared with SOC-treated and untreated ADHD patients. SOC was assumed to consist of a combination of short-, intermediate-, and long-acting ADHD stimulant and non-stimulant medications. DXR crash risk was assumed equivalent to the non-ADHD population risk, as supported by trial data. Crash risk for untreated and SOC-treated ADHD patients were assumed to be 99% and 52% higher than the general US population, respectively. Model outcomes included the cost impact (medication- and crash-related costs) and the number of crashes, injuries, and fatalities avoided with DXR. Results: Treatment with DXR would avoid 0.82 crashes, 0.016 injuries, and 0.036 fatalities per year compared with untreated patients, and 0.036 crashes, 0.007 injuries, and 0.0001 fatalities per year compared with SOC-treated patients. Compared with a population of 25% SOC-treated patients and 75% untreated patients, DXR use would save an average of $4581 per person per year across all age groups when priced at $80 per month, assuming all SOC-treated and untreated patients utilized DXR. When the value of quality-of-life improvement is considered, savings increase over 7-fold. Discussion: Outcomes suggest that DXR may be an economically beneficial treatment compared with SOC for ADHD patients. Conclusions: The economic model showed that DXR is cost-saving compared with no treatment and SOC by reducing the number of motor vehicle crashes in the ADHD population.


  • Open Access

    Pancreatic stone protein point-of-care testing can reduce healthcare expenditure in sepsis

    by John E. Schneider, Katherine Dick, Jacie T. Cooper, Nadine Chami

    Background: Sepsis is a life-threatening organ dysfunction in response to infection. Early recognition and rapid treatment are critical to patient outcomes and cost savings, but sepsis is difficult to diagnose because of its non-specific symptoms. Biomarkers such as pancreatic stone protein (PSP) offer rapid results with greater sensitivity and specificity than standard laboratory tests. Methods: This study developed a decision tree model to compare a rapid PSP test to standard of care in the emergency department (ED) and intensive care unit (ICU) to diagnose patients with suspected sepsis. Key model parameters included length of hospital and ICU stay, readmission due to infection, cost of sepsis testing, length of antibiotic treatment, antibiotic resistance, and clostridium difficile infections. Model inputs were determined by review of sepsis literature. Results: The rapid PSP test was found to reduce costs by $1688 per patient in the ED and $3315 per patient in the ICU compared to standard of care. Cost reductions were primarily driven by the specificity of PSP in the ED and the sensitivity of PSP in the ICU. Conclusions: The results of the model indicate that PSP testing is cost saving compared to standard of care in diagnosis of sepsis. The abundance of sepsis cases in the ED and ICU make these findings important in the clinical field and further support the potential of sensitive and specific markers of sepsis to not only improve patient outcomes but also reduce healthcare expenditures.


  • Open Access

    Cost impact analysis of novel host-response diagnostic for patients with community-acquired pneumonia in the emergency department

    by John E. Schneider, Jacie T. Cooper

    Background. There is significant over-prescription of antibiotics for suspected community-acquired pneumonia (CAP) patients as bacterial and viral pathogens are difficult to differentiate. To address this issue, a host response diagnostic called MeMed BV® (MMBV) was developed that accurately differentiates bacterial and viral infection at the point of need by integrating measurements of multiple biomarkers. A literature-based cost-impact model was developed that compared the cost impact and clinical benefits between using standard of care diagnostics combined with MMBV relative to standard of care diagnostics alone. Methods. The patient population was stratified according to the patient severity index, and cost savings were considered from payer and provider perspectives. Four scenarios were considered. The main analysis considers the cost impact of differences in antibiotic stewardship and resulting adverse events. The first, second, and third scenarios combine the impacts on antibiotic stewardship with changes in hospital admission probability, length of hospital stay and diagnostic related group (DRG) reallocation, and hospital admission probability, length of stay, and DRG reallocation in combination, respectively. Results. The main analysis results show overall per-patient savings of $37 for payers and $223 for providers. Scenarios 1, 2, and 3 produced savings of $137, $189, and $293 for payers, and $339, $713, and $809 for providers, respectively. Limitations. Models are simulations of real-world clinical processes, and are not sensitive to variations in clinical practice driven by differences in physician practice styles, differences in facility-level practice patterns, and patient comorbidities expected to exacerbate the clinical impact of CAP. Hospital models are limited to costs and do not consider differences in revenue associated with each approach. Conclusions. Introducing MMBV to the current SOC diagnostic process is likely to be cost saving to both hospitals and payers when considering impacts on antibiotic distribution, hospital admission rate, hospital LOS, and DRG reallocation.